Comparison of media and serum supplementation for generation of monophosphoryl lipid A/interferon-γ-matured type I dendritic cells for immunotherapy

Cytotherapy

Volumn 16, Issue 6, 2014, Pages 826-834

  Kolanowski, Sonja T H M ^a   Sritharan, Lathees ^a   Lissenberg Thunnissen, Suzanne N ^a   Van Schijndel, Gijs M W ^a   Van Ham, S Marieke ^a   Brinke, Anja Ten ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Clinical grade dendritic cells; Culture media; Immunotherapy; Monophosphoryl lipid A; Serum

Indexed keywords

B7 ANTIGEN; CD40 ANTIGEN; CD83 ANTIGEN; CD86 ANTIGEN; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 17; INTERLEUKIN 4; INTERLEUKIN 6; PHOSPHORYL LIPID A; SECONDARY LYMPHOID TISSUE CHEMOKINE; TUMOR NECROSIS FACTOR ALPHA; CULTURE MEDIUM; LIPID A;

ARTICLE; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CELL ADHESION; CELL MATURATION; CELL MIGRATION; CELL POLARITY; CELL PROLIFERATION; CELL SIZE; CELL STIMULATION; CELL SURVIVAL; CONTROLLED STUDY; CULTURE MEDIUM; CYTOKINE PRODUCTION; DENDRITIC CELL; GOOD MANUFACTURING PRACTICE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SERUM; TH1 CELL; TYPE 1 DENDRITIC CELL; ANALOGS AND DERIVATIVES; BIOLOGICAL THERAPY; CELL DIFFERENTIATION; CYTOLOGY; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; NEOPLASMS; PROCEDURES; TRANSPLANTATION;

CELL DIFFERENTIATION; CELL PROLIFERATION; CELL- AND TISSUE-BASED THERAPY; CULTURE MEDIA; DENDRITIC CELLS; HUMANS; IMMUNOTHERAPY; INTERFERON-GAMMA; LIPID A; NEOPLASMS; TH1 CELLS;

EID: 84899739242     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.1016/j.jcyt.2013.12.005     Document Type: Article

References (28)

1. Mailliard R.B., Wankowicz-Kalinska A., Cai Q., Wesa A., Hilkens C.M., Kapsenberg M.L., et al. Alpha-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity. Cancer Res 2004, 64:5934-5937.
2. de Vries I.J., Eggert A.A., Scharenborg N.M., Vissers J.L., Lesterhuis W.J., Boerman O.C., et al. Phenotypical and functional characterization of clinical grade dendritic cells. JImmunother 2002, 25:429-438.
3. ten Brinke A., van Schijndel G., Visser R., de Gruijl T.D., Zwaginga J.J., van Ham S.M. Monophosphoryl lipid A plus IFNgamma maturation of dendritic cells induces antigen-specific CD8+ cytotoxic T cells with high cytolytic potential. Cancer Immunol Immunother 2010, 59:1185-1195.
4. ten Brinke A., Karsten M.L., Dieker M.C., Zwaginga J.J., van Ham S.M. The clinical grade maturation cocktail monophosphoryl lipid A plus IFNgamma generates monocyte-derived dendritic cells with the capacity to migrate and induce Th1 polarization. Vaccine 2007, 25:7145-7152.
5. Royer P.J., Tanguy-Royer S., Ebstein F., Sapede C., Simon T., Barbieux I., et al. Culture medium and protein supplementation in the generation and maturation of dendritic cells. Scand J Immunol 2006, 63:401-409.
6. Loudovaris M., Hansen M., Suen Y., Lee S.M., Casing P., Bender J.G. Differential effects of autologous serum on CD34(+) or monocyte-derived dendritic cells. JHematother Stem Cell Res 2001, 10:569-578.
7. Jeras M., Bergant M., Repnik U. In vitro preparation and functional assessment of human monocyte-derived dendritic cells-potential antigen-specific modulators of in vivo immune responses. Transpl Immunol 2005, 14:231-244.
8. Rey-Giraud F., Hafner M., Ries C.H. In vitro generation of monocyte-derived macrophages under serum-free conditions improves their tumor promoting functions. PLoS One 2012, 7:e42656.
9. Bender A., Sapp M., Schuler G., Steinman R.M., Bhardwaj N. Improved methods for the generation of dendritic cells from nonproliferating progenitors in human blood. JImmunol Methods 1996, 196:121-135.
10. Napoletano C., Pinto D., Bellati F., Taurino F., Rahimi H., Tomao F., et al. Acomparative analysis of serum and serum-free media for generation of clinical grade DCs. JImmunother 2007, 30:567-576.
11. Peng J.C., Thomas R., Nielsen L.K. Generation and maturation of dendritic cells for clinical application under serum-free conditions. JImmunother 2005, 28:599-609.
12. Duperrier K., Eljaafari A., Dezutter-Dambuyant C., Bardin C., Jacquet C., Yoneda K., et al. Distinct subsets of dendritic cells resembling dermal DCs can be generated in vitro from monocytes, in the presence of different serum supplements. JImmunol Methods 2000, 238:119-131.
13. Meyer-Wentrup F., Burdach S. Efficacy of dendritic cell generation for clinical use: recovery and purity of monocytes and mature dendritic cells after immunomagnetic sorting or adherence selection of CD14+ starting populations. JHematother Stem Cell Res 2003, 12:289-299.
14. Motta M.R., Castellani S., Rizzi S., Curti A., Gubinelli F., Fogli M., et al. Generation of dendritic cells from CD14+ monocytes positively selected by immunomagnetic adsorption for multiple myeloma patients enrolled in a clinical trial of anti-idiotype vaccination. Br J Haematol 2003, 121:240-250.
15. Macke L., Garritsen H.S., Meyring W., Hannig H., Pagelow U., Wormann B., et al. Evaluating maturation and genetic modification of human dendritic cells in a new polyolefin cell culture bag system. Transfusion 2010, 50:843-855.
16. Tawab A., Fan Y., Read E.J., Kurlander R.J. Effect of ex vivo culture duration on phenotype and cytokine production by mature dendritic cells derived from peripheral blood monocytes. Transfusion 2009, 49:536-547.
17. Jakobsen M.A., Moller B.K., Lillevang S.T. Serum concentration ofthe growth medium markedly affects monocyte-derived dendritic cells' phenotype, cytokine production profile and capacities to stimulate in MLR. Scand J Immunol 2004, 60:584-591.
18. Schumann R.R. Old and new findings on lipopolysaccharide-binding protein: a soluble pattern-recognition molecule. Biochem Soc Trans 2011, 39:989-993.
19. Mata-Haro V., Cekic C., Martin M., Chilton P.M., Casella C.R., Mitchell T.C. The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4. Science 2007, 316:1628-1632.
20. Carlos C.A., Dong H.F., Howard O.M., Oppenheim J.J., Hanisch F.G., Finn O.J. Human tumor antigen MUC1 is chemotactic for immature dendritic cells and elicits maturation but does not promote Th1 type immunity. JImmunol 2005, 175:1628-1635.
21. Rughetti A., Pellicciotta I., Biffoni M., Backstrom M., Link T., Bennet E.P., et al. Recombinant tumor-associated MUC1 glycoprotein impairs the differentiation and function of dendritic cells. JImmunol 2005, 174:7764-7772.
22. Hiltbold E.M., Vlad A.M., Ciborowski P., Watkins S.C., Finn O.J. The mechanism of unresponsiveness to circulating tumor antigen MUC1 is a block in intracellular sorting and processing by dendritic cells. JImmunol 2000, 165:3730-3741.
23. Huang J., Jochems C., Talaie T., Anderson A., Jales A., Tsang K.Y., et al. Elevated serum soluble CD40 ligand in cancer patients may play an immunosuppressive role. Blood 2012, 120:3030-3038.
24. Muthuswamy R., Mueller-Berghaus J., Haberkorn U., Reinhart T.A., Schadendorf D., Kalinski P. PGE(2) transiently enhances DC expression of CCR7 but inhibits the ability of DCs to produce CCL19 and attract naive T cells. Blood 2010, 116:1454-1459.
25. Cyster J.G. Chemokines, sphingosine-1-phosphate, and cell migration in secondary lymphoid organs. Annu Rev Immunol 2005, 23:127-159.
26. Sallusto F., Mackay C.R., Lanzavecchia A. The role of chemokine receptors in primary, effector, and memory immune responses. Annu Rev Immunol 2000, 18:593-620.
27. Hansen M., Hjorto G.M., Donia M., Met O. Comparison of clinical grade type 1 polarized and standard matured dendritic cells for cancer immunotherapy. Vaccine 2013, 31:639-646.
28. Lehner M., Morhart P., Stilper A., Holter W. Functional characterization of monocyte-derived dendritic cells generated under serum-free culture conditions. Immunol Lett 2005, 99:209-216.